SEC Form 4/A · accession 0001171843-15-000300

Xenon Pharmaceuticals Inc. · XENE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

This is an amendment (Form 4/A). It replaces an earlier filing for the same period.

Reporting owner

Director

Period of report

Jan 7, 2015

Accepted (ET)

Jan 21, 2015 · 8:13 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001582313

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Shares^F1	Jan 7, 2015	M	3,497	$4.98	A	3,497	D
Common Shares^F2,F3,F4	Jan 7, 2015	F	953	$22.28	D	2,544	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F1,F5	$4.98	Jan 7, 2015	M	3,497	D	—	May 8, 2015	Common Shares	3,497	0	D

F1The exercise price was converted from $6.07 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
F2The Reporting Person's original Form 4 omitted to report shares withheld by the Company in connection with the exercise of the Stock Option.
F3Pursuant to the terms of a Lock-up Agreement executed by the Reporting Person in favor of the underwriters of the Company's initial public offering in November 2014 (the "Lock-up"), the Company withheld the number of shares set forth above pursuant to a net settlement permitted under the terms of the Lock-up. No shares were sold by the Reporting Person in connection with the exercise and the common shares issued as a result of the exercise are subject to the terms of the Lock-up.
F4Represents the closing price of the Company's common shares on January 6, 2015, converted to a Canadian dollar amount for purposes of net settlement calculations.
F5The shares subject to the option fully vested on January 1, 2008.